Original Article

Correlation between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study


Background: Non-alcoholic fatty liver disease (NAFLD) is one of the important health issues with high prevalence worldwide. However, there is no approved medication for that. As one of the indicators of metabolic syndrome, uric acid might play a role in the pathogenesis of NAFLD. In this study, we aimed to determine the correlation between serum uric acid level, liver enzymes, and ultrasonographic grading of NAFLD.

Methods: This cross-sectional study included patients aged 18-65 with NAFLD. Patients with other metabolic disorders and a history of using alcohol or medications that alter uric acid levels were excluded. The patients' serum uric acid, alanine aminotransferase (ALT), aspartate aminotransferase (AST) levels, and ultrasonographic grading of NAFLD at baseline, third month, and sixth month were collected.

Results:  Of the 3000 patients, 500 patients met the eligibility criteria. The results showed that there is a significant positive relationship between ALT and serum uric acid level at the first (P = .01), third (P = .01), and sixth month (P = .01). Furthermore, there was a significant positive correlation between AST and serum uric acid level at the sixth month (P = 0.001). The comparison of 249 patients' ultrasonographic grading showed no significant correlation with serum uric acid levels.

Conclusion: To conclude, the serum uric acid level significantly correlates with ALT and AST over six months but not with the ultrasonographic grading. Further studies are required to determine the role of uric acid-lowering agents in the treatment of NAFLD.

1. Younossi ZM. The epidemiology of nonalcoholic steatohepatitis. Clin Liver Dis. 2018;11(4):92-4.
2. Salt WB, 2nd. Nonalcoholic fatty liver disease (NAFLD): a comprehensive review. J Insur Med. 2004;36(1):27-41.
3. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686-90.
4. Ipekci SH, Basaranoglu M, Sonsuz A. The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2003;36(4):371.
5. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745-50.
6. Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol. 2000;95(11):3206-10.
7. Berger D, Desai V, Janardhan S. Con: liver biopsy remains the gold standard to evaluate fibrosis in patients with nonalcoholic fatty liver disease. Clin Liver Dis (Hoboken). 2019;13(4):114-16.
8. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/ nonalcoholic steatohepatitis. World J Gastroenterol.. 2014;20(2):475-85.
9. Khov N, Sharma A, Riley TR. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(22):6821- 25.
10. Pavlides M, Cobbold JF. Non-alcoholic fatty liver disease. Medicine. 2015;43(10):585-89.
11. Collier J. Clinical and biochemical assessment of symptomatic and asymptomatic liver disease. Medicine. 2015;43(10):557-61.
12. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic liver disease (NAFLD). Ann Hepatol. 2009;8(S1):S4-S8.
13. Lin SZ, Chen YW, Fan JG. Non-alcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: Conceptual changes for clinicians, researchers and patients. J Dig Dis. 2020;21(11):604-9.
14. Hediger MA, Johnson RJ, Miyazaki H, Endou H. Molecular physiology of urate transport. Physiology. 2005;20(2):125-33.
15. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol. 2009;50(5):1029-34.
16. Yuan H, Yu C, Li X, et al. Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies. J Clin Endocrinol Metab. 2015;100(11):4198-207.
17. Quinones Galvan A, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268(1):E1-E5.
18. García‐Ruiz I, Rodríguez‐Juan C, Díaz‐Sanjuan T, et al. Uric acid and anti‐TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology. 2006;44(3):581-91.
19. Ryu S, Chang Y, Kim S-G, Cho J, Guallar E. Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism. 2011;60(6):860-6.
20. Wang CC, Tseng TC, Hsieh TC, et al. Severity of fatty liver on ultrasound correlates with metabolic and cardiovascular risk. Kaohsiung J Med Sci.. 2012;28(3):151-60.
21. Moghaddasifar I, Lankarani KB, Moosazadeh M, Afshari M, Ghaemi A, Aliramezany M, et al. Prevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in Iran. Int J Organ Transplant Med. 2016;7(3):149-60.
22. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367-79.
23. Gong S, Song J, Wang L, Zhang S, Wang Y. Hyperuricemia and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2016;28(2):132-38.
24. Lonardo A, Loria P, Leonardi F, et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig liver Dis. 2002;34(3):204-11.
25. Ryu S, Chang Y, Kim SG, Cho J, Guallar E. Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism: clinical and experimental. 2011;60(6):860-66.
26. Xu C, Wan X, Xu L, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. J Hepatol. 2015;62(6):1412-19.
27. Petta S, Cammà C, Cabibi D, Di Marco V, Craxì A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;34(7):757-66.
28. Sertoglu E, Ercin CN, Celebi G, et al. The relationship of serum uric acid with non-alcoholic fatty liver disease. Clin Biochem. 2014;47(6):383-88.
29. Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. PloS one. 2010;5(7):e11578.
30. Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver
ultrasound data from the National Health and Nutrition Examination Survey. Metabolism. 2013;62(3):392-99.
IssueVol 10, No 4 (Autumn 2022) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/jpc.v10i4.11582
Alanine transaminase Aspartate aminotransferase Gastroenterology Liver diseases Ultrasonography

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Khani E, Khoshbaten M, Pourkarim F, Asghari Jafarabadi M, Shaseb E. Correlation between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study. J Pharm Care. 2022;10(4):218-222.